Over 13.8 million cancer survivors currently live in the United States (Stubblefield, Schmitz, & Ness, 2013), of which about 300,000 are adult survivors of childhood cancer. As new chemotherapeutic agents are introduced, the percentage of adult cancer survivors will increase – as will the number of adults who suffer late neurocognitive late effects of these treatments, which may not appear until 20 years after treatment.
Adult cancer survivors face a number of long-term physical effects of childhood chemotherapy, including hearing loss (Yasui, 2013), cardiotoxicity, infertility, peripheral neuropathy, musculoskeletal damage, and extreme fatigue (Kiserud, Dahl, Loge, & Fosså, 2014). Over the past 10 years, however, there has been increasing acceptance of chemotherapy-...
